Every letter we have printed

One practical note from the other side of the counter. When a customer asks us for the gradient we send it. When a customer asks a reseller, the reseller does not have it, because they were sent a PDF with a number on it. The gap you are describing is often two links down the chain rather than at the laboratory.

The silence is not a conspiracy. It is what happens when nobody has an obligation, nobody has a question and the instrument that would answer it sits in a different laboratory from the one everybody already uses.

The reason nobody discusses this is partly that discussing it invites a use-case that the research-use framing exists to avoid. The silence is structural rather than evasive.

The recombinant factor C assay deserves a mention. It removes the reliance on a wild-harvested reagent, it is now recognised in more than one pharmacopoeia, and for a laboratory setting up new it is the sensible starting point. Your piece treats the lysate assay as the only option.

The commercial literature describes maintenance as a phase; the trial literature describes it as an extension arm; the people I correspond with describe it as the rest of their life. Three timescales, one word, and most confusion in this area comes from the mismatch.

Analytical quality matters more over a long horizon than a short one, which is a point this publication is well placed to make. A material used once is a single exposure; a material used for years is a cumulative one, and the standard a buyer applies should rise accordingly.

Where a reason is recorded by a clinician rather than by the person, the categories reflect what the clinician was listening for. That is not a criticism of clinicians; it is a property of any coded record, and it is rarely acknowledged in the resulting statistics.

Arrival condition should be recorded by the buyer at the moment of opening, in writing, with a photograph. It takes a minute and it is the only record of that leg that will ever exist.

Retest date and expiry date are different concepts and the trade uses them interchangeably. A retest date says the material may be re-examined and used if it still conforms; an expiry says it may not. Printing one and meaning the other is a small dishonesty that has become a convention.

The most reported response in every account I have collected is to wait, and waiting is not described as a strategy in any formal source. The commonest behaviour in the field has no name in the literature.

Management strategies circulate in this area with very little trial support, and the honest way to present them is as reported practice rather than as evidence. Your piece does that; a great deal of adjacent coverage does not.

Weight-bearing changes as mass changes, and the mechanical loading on the skeleton changes with it. Any bone finding in a mass-loss study is confounded by that mechanically, quite apart from anything pharmacological.

Precision error on a densitometer is a published figure for each machine and it is comparable in size to the changes being reported. Any study reporting a change smaller than its own least significant change is reporting noise, and some do.

The distinction between maintaining a result and maintaining a dose is collapsed everywhere. They are separable questions and the published data addresses the second far better than the first.

The dose that produced the change and the dose that holds it need not be the same, and the pharmacology gives no strong reason to assume they are. That is a hypothesis worth testing and at present it is being tested informally by a great many people.

The reasons people give at the time and the reasons they give a year later are not the same. Retrospective accounts are tidier and more causal, and any dataset assembled after the fact should be read with that in mind.

A reason absent from every list: the person stopped believing the material was what it claimed to be. In a market where that is a live question, it is an obvious category, and no clinical taxonomy would ever include it.

Reported adherence in the maintenance phase of published trials is high and self-reported adherence outside them is not measured at all. Any comparison between trial outcomes and general experience has that gap in it and rarely acknowledges it.

The invisible category that worries me most is the residual solvent, because it has no chromophore, ionises badly and is present by design rather than by accident. It is measured by a completely different instrument and almost never ordered.

Aggregates are the other invisible class, and for a different reason: they do not survive the ionisation. A sample that is substantially aggregated can give an entirely clean monomer spectrum, because the instrument is reporting on what made it into the gas phase.

Adducts deserve a paragraph. Sodium and potassium are everywhere in glassware and buffers, they shift the observed mass by amounts that look meaningful, and an analyst who is not expecting them can report a modification that is really a salt. It is the most common false positive I see in this trade.

Charge-state distribution is diagnostic and almost always discarded. A peptide that normally presents as a triply and quadruply charged pair, appearing this time as a broad ladder, is telling you something about its conformation or its buffer. The information is in the file and never in the summary.

The material this publication covers is not approved for human use in any jurisdiction, which changes what a safety discussion can even mean. A pharmacovigilance system attaches to an approved product and there is no analogous system here at all.

The reporting asymmetry is worth naming. Severe events are newsworthy and mild ones are not, so the visible discussion is drawn from the tail of a distribution and read as though it described the middle.

Gallbladder motility gets a sentence in most reviews and deserves more, since it is a distinct mechanism with a distinct time course and it accounts for a category of reported events that the emptying story does not explain.

Baseline transit varies enormously across a healthy population and is almost never measured before the intervention. A study without baseline measurement is estimating a change from an assumed starting point.

Your explanation of endotoxin units is the clearest I have read outside a pharmacopoeia, and the unit is where most confusion starts. A limit expressed per milligram and a limit expressed per container are different constraints, and which one applies depends on how much material is used at once.

The chromogenic and gel-clot methods report on different scales and are quoted interchangeably. Where a figure appears without the method, it cannot be compared with any other figure.

Why did you submit only two vials for sterility testing when the whole article argues that the sample size is the problem? Two is worse than twenty by exactly the argument you make.

Coring is the failure mode that follows repeated withdrawals from one stopper, and it produces exactly the particulate your article warns about. The number of entries a closure is qualified for is a real specification and it is never stated on anything sold in this market.

Particulate matter deserves its own paragraph. Glass delamination, stopper fragments and fibres are all real findings in vialled products, and the only examination most buyers perform is a glance at a powder they cannot see through. Look again after reconstitution and against a dark background.

Injecting into an area about to be exercised heavily raises local blood flow and can alter absorption. It is a small effect for weekly molecules and worth a sentence for completeness.

A simple scheme beats a complicated one because it gets followed. Dividing the available area into quadrants and moving on a fixed rotation is enough, and elaborate maps do not survive contact with a busy week.

The convenient reconstitution is the one that makes the arithmetic trivial rather than the one that makes the volume small. Choosing a diluent volume so that a graduation corresponds to a round figure removes an entire class of error, and it costs nothing but a moment’s thought before the needle goes in.

Syringes marked to fifty units exist and hold half a millilitre, with the same numbering scale. Somebody who has learned the arithmetic on a hundred-unit barrel and then picks up a fifty will get the volume right and the assumption wrong. It is worth a warning line.

A tenfold error is the characteristic failure of decimal arithmetic under any circumstances, and every account of a miscalculation I have read in this context is a factor of ten. That is a signature and it points at where the safeguards should sit.

Adding a second medicine to manage the effects of the first is a real decision with its own consequences, and it is discussed far too casually in general forums. It belongs with a clinician who knows the whole picture, and this letter is not advice to anyone.

Where an approach requires a clinician, saying so plainly is the most useful sentence in the piece. A great deal of published guidance in this area assumes access that many readers do not have, and pretending otherwise helps nobody.

The ethics of a withdrawal design deserve a sentence somewhere. Randomising somebody to lose an effect they have obtained is defensible and it is not trivial, and the consent process for these studies is more interesting than the results.

A design nobody has run: withdraw, follow, then offer resumption and follow again. It would answer the question most readers actually have, and it is longer and more expensive than anybody has been willing to fund.